Myriad Genetics Inc. (MYGN: Quote) Thursday said that the U.S. Court of Appeals for the Federal Circuit declared its composition of matter claims covering isolated DNA of the BRCA 1 and BRCA 2 genes are patent-eligible material under Section 101 of the U.S. Patent Act. This decision reinstates the prior decision by the Court on July 29, 2011.
"We are very pleased with the favorable decision the Court rendered today which again confirmed that isolated DNA is patentable," said Peter Meldrum, President and CEO of Myriad Genetics.
"Importantly, the Court agreed with Myriad that isolated DNA is a new chemical matter with important utilities which can only exist as the product of human ingenuity," Meldrum added.
Click here to receive FREE breaking news email alerts for Myriad Genetics Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com